Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 19/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437443 | 0.94 | ROCK1 (0.62) | ROCK1CYP3A4CITJAK2FLT3 | |
| SCHEMBL437441 | 0.91 | ROCK1 (0.65) | ROCK1CYP3A4CITJAK2FLT3 | |
| SCHEMBL12854833 | 0.91 | ROCK1 (0.66) | ROCK1CYP3A4CITJAK2FLT3 | |
| SCHEMBL437408 | 0.90 | ROCK1 (0.65) | ROCK1CYP3A4CITJAK2FLT3 | |
| SCHEMBL437454 | 0.90 | ROCK1 (0.65) | ROCK1CYP3A4CITJAK2FLT3 | |
| SCHEMBL438733 | 0.89 | ROCK1 (0.82) | ROCK1CYP3A4CITJAK2FLT3 | |
| SCHEMBL12123149 | 0.85 | ROCK1 (0.62) | ROCK1CYP3A4CITJAK2FLT3 | |
| SCHEMBL438740 | 0.83 | ROCK1 (0.74) | ROCK1CYP3A4CITJAK2FLT3 | |
| SCHEMBL439714 | 0.83 | ROCK1 (0.60) | ROCK1CYP3A4ROCK2PRKACA | |
| SCHEMBL436512 | 0.82 | ROCK1 (0.65) | ROCK1CYP3A4CITJAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, MYLK | ROCK1 4/4885CYP3A4 3859/4885CIT 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.